JP2022544485A5 - - Google Patents
Info
- Publication number
- JP2022544485A5 JP2022544485A5 JP2022508487A JP2022508487A JP2022544485A5 JP 2022544485 A5 JP2022544485 A5 JP 2022544485A5 JP 2022508487 A JP2022508487 A JP 2022508487A JP 2022508487 A JP2022508487 A JP 2022508487A JP 2022544485 A5 JP2022544485 A5 JP 2022544485A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- combination therapy
- day cycle
- days
- ipatasertib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025064712A JP2025121905A (ja) | 2019-08-12 | 2025-04-10 | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962885732P | 2019-08-12 | 2019-08-12 | |
| US62/885,732 | 2019-08-12 | ||
| US201962935526P | 2019-11-14 | 2019-11-14 | |
| US62/935,526 | 2019-11-14 | ||
| PCT/US2020/045584 WO2021030248A1 (en) | 2019-08-12 | 2020-08-10 | Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064712A Division JP2025121905A (ja) | 2019-08-12 | 2025-04-10 | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022544485A JP2022544485A (ja) | 2022-10-19 |
| JP2022544485A5 true JP2022544485A5 (cg-RX-API-DMAC7.html) | 2023-08-21 |
| JP7667132B2 JP7667132B2 (ja) | 2025-04-22 |
Family
ID=72193647
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022508487A Active JP7667132B2 (ja) | 2019-08-12 | 2020-08-10 | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 |
| JP2025064712A Pending JP2025121905A (ja) | 2019-08-12 | 2025-04-10 | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025064712A Pending JP2025121905A (ja) | 2019-08-12 | 2025-04-10 | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11576919B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4013419A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7667132B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114206345A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202120096A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021030248A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI719765B (zh) | 2018-12-19 | 2021-02-21 | 美商建南德克公司 | 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療 |
| US11576919B2 (en) * | 2019-08-12 | 2023-02-14 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant |
| WO2023107525A1 (en) * | 2021-12-10 | 2023-06-15 | Eli Lilly And Company | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor |
| IL320302A (en) * | 2022-10-17 | 2025-06-01 | Astrazeneca Ab | SERD combinations for cancer treatment |
| CN121057581A (zh) * | 2023-05-05 | 2025-12-02 | 阿斯利康(瑞典)有限公司 | 用于在治疗乳腺癌中使用的卡帕塞替尼、cdk4/6抑制剂和氟维司群的组合 |
| WO2024255883A1 (zh) * | 2023-06-14 | 2024-12-19 | 南京正大天晴制药有限公司 | Akt抑制剂在制备预防或治疗乳腺癌药物中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012135781A1 (en) * | 2011-04-01 | 2012-10-04 | Genentech, Inc. | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use |
| KR102678074B1 (ko) * | 2012-05-17 | 2024-06-26 | 제넨테크, 인크. | 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법 |
| WO2015136016A2 (en) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| WO2017161253A1 (en) * | 2016-03-18 | 2017-09-21 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
| BR112019002007B1 (pt) * | 2016-08-10 | 2024-01-16 | F. Hoffmann-La Roche Ag | Composição farmacêutica e uso de uma composição farmacêutica |
| WO2018233620A1 (zh) | 2017-06-21 | 2018-12-27 | 江苏恒瑞医药股份有限公司 | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 |
| US11576919B2 (en) | 2019-08-12 | 2023-02-14 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant |
| CN114830258A (zh) * | 2019-09-16 | 2022-07-29 | 斯坦福大学托管董事会 | 基于乳腺癌的分子表征的治疗方法 |
-
2020
- 2020-08-10 US US16/989,528 patent/US11576919B2/en active Active
- 2020-08-10 TW TW109127081A patent/TW202120096A/zh unknown
- 2020-08-10 CN CN202080056620.0A patent/CN114206345A/zh active Pending
- 2020-08-10 EP EP20761063.5A patent/EP4013419A1/en active Pending
- 2020-08-10 WO PCT/US2020/045584 patent/WO2021030248A1/en not_active Ceased
- 2020-08-10 JP JP2022508487A patent/JP7667132B2/ja active Active
-
2023
- 2023-01-25 US US18/101,377 patent/US12083129B2/en active Active
-
2024
- 2024-08-28 US US18/817,828 patent/US20250161322A1/en active Pending
-
2025
- 2025-04-10 JP JP2025064712A patent/JP2025121905A/ja active Pending